Stock market crash: UK shares that I think are too cheap to ignore

Even months after the stock market crash there are still opportunities to pick up cheap shares, says Andy Ross.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The recovery from this year’s earlier stock market crash has been a slow process for most shares. Now even US tech shares are falling. Closer to home, I think the crash means there are UK shares that are very cheap.

Lagging behind its rivals but with potential 

One is the big pharma group GlaxoSmithKline (LSE: GSK), which is involved in finding a vaccine for Covid-19. For me that’s not the reason to invest though. I find the possibility of a R&D-led turnaround, and the potential that has to make GlaxoSmithKline a high-yielding, dividend growth share, to be very appealing.

Progress towards on path has been slower than some may like. Rival AstraZeneca is much further ahead. But under CEO Emma Walmsley, it’s progressing. The group will spin out its consumer healthcare business within the next three years. It has also spent money on acquiring TESARO, for example, to beef up its oncology portfolio.

I believe for long-term investors, if Glaxo can come anywhere close to replicating AstraZeneca’s R&D success, then the shares are far too cheap. AstraZeneca has a trailing price-to-earnings multiple of around 100, putting into perspective just how cheap Glaxo shares are. 

The shares are cheaper even now, after falling sharply recently. They trade on a P/E of under 12 which to me represents good value compared to other pharma companies and the market more generally.

A cheap share hit hard by the stock market crash

Barratt Developments (LSE: BDEV) could face some short-term pressures from regulatory action concerning leaseholds. It’s unclear as yet what action that could lead to, although the issue itself isn’t particularly new.

More broadly the government has been supporting the sector. In addition to the Stamp Duty cut, Help to Buy is still supporting sales and there are rumours it could be extended even further.

Barratt shares were cheap even before the pandemic because of Brexit and probably because of the possible ending of Help to Buy in 2021. Now the shares are even cheaper as the pandemic closed down the industry earlier this year. So the housebuilders are still playing catchup. They have mostly still to reintroduce their dividends which were cut in response to Covid-19. 

I think the shares are a potentially profitable investment because of their cheapness – they trade on a P/E of 14 – and the potential for the dividend to be reintroduced. Rival Persimmon has already announced the resumption of payments, albeit at a lower rate. Then thirdly, the high levels of cash held by Barratt and its rivals will see them through this period of lower sales.

When I look at GlaxoSmithKline and Barratt Developments, I see two shares that are great value after the stock market crash. To me they are too cheap to ignore, and could make investors money in the future both from share price growth and from dividends.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Andy Ross owns shares in AstraZeneca and Persimmon. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Want a £1,320 passive income in 2025? These 2 UK shares could deliver it!

These dividend stocks have long histories of paying large and growing dividends. They're tipped to deliver more huge rewards in…

Read more »

Investing Articles

With P/E ratios below 8, I think these FTSE 250 shares are bargains!

The forward P/E ratios on these FTSE 250 shares are far below the index average of 14.1 times. I think…

Read more »

Investing Articles

Are stocks and shares the only way to become an ISA millionaire?

With Cash ISAs offering 5%, do stocks and shares make sense at the moment? Over the longer term, Stephen Wright…

Read more »

Dividend Shares

4,775 shares in this dividend stock could yield me £1.6k a year in passive income

Jon Smith explains how he can build passive income from dividend payers via regular investing that can compound quickly.

Read more »

Investing Articles

Is the Rolls-Royce share price heading to 655p? This analyst thinks so

While the Rolls-Royce share price continues to thrash the FTSE 100, this writer has a couple of things on his…

Read more »

Investing Articles

What’s going on with the National Grid share price now?

Volatility continues for the National Grid share price. Is this a warning sign for investors to heed or a buying…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
US Stock

This is a huge week for Nvidia stock

It’s a make-or-break week for Nvidia stock as the company is posting its Q3 earnings on Wednesday. Here’s what investors…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

After crashing 50% this FTSE value stock looks filthy cheap with a P/E of just 9.1%

Harvey Jones has some unfinished business with this FTSE 100 value stock, which he reckons has been harshly treated by…

Read more »